US drug spending hits $425 billion

A systematic review of reference pricing: implications for US prescription drug spending.

Given rising pharmaceutical expenditures and the widespread use of reference pricing as a costcontainment instrument abroad, we systematically reviewed the evidence evaluating reference pricing policies. We performed a structured electronic search of peer-reviewed journals for studies published before that reported on the effects of reference pricing policies on medication use, payer and patien...

Spending on New Drug Development

This paper replicates DiMasi et al (2003, 2004) estimates of expenditure on new drug development using publicly available data. The paper estimates that average expenditure on drugs in human clinical trials is around $25m per year, with $18m per year on drugs in Phase 1, $33m on drugs in Phase 2 and $19m per year on drugs in Phase 3 of the human clinical trials. The paper’s estimated expenditur...

What can 1 billion trials tell us about visual search?

Mobile technology (e.g., smartphones and tablets) has provided psychologists with a wonderful opportunity: through careful design and implementation, mobile applications can be used to crowd source data collection. By garnering massive amounts of data from a wide variety of individuals, it is possible to explore psychological questions that have, to date, been out of reach. Here we discuss 2 ex...

Sources of variation in provincial drug spending.

A New Focus on Prescription Drug Spending.